FDA Events for Tesla (TSLA)
This section highlights FDA-related milestones and regulatory updates for drugs developed by Tesla (TSLA).
Over the past two years, Tesla has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
CONVOY. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
CONVOY - FDA Regulatory Timeline and Events
CONVOY is a drug developed by Tesla for the following indication: To test the Brain-to-Computer-interface (BCI) N1 Implant with assistive robotic arms.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- CONVOY
- Announced Date:
- November 29, 2024
- Indication:
- To test the Brain-to-Computer-interface (BCI) N1 Implant with assistive robotic arms.
Announcement
Tesla Inc. has introduced a major enhancement to its humanoid robot, Optimus, featuring new hands.
AI Summary
Tesla Inc. has unveiled a major upgrade to its humanoid robot, Optimus, by introducing new, advanced hands. The updated hands, showcased when the robot caught a tennis ball, highlight the company’s push toward replicating human hand capabilities. With improved dexterity, Optimus aims to perform a wider range of tasks and enhance its interaction capabilities. CEO Elon Musk has previously noted plans to boost the robot’s hand functionality to achieve about 22 degrees of freedom—close to the 27 degrees offered by human hands—demonstrating Tesla’s commitment to refining robotic movements and versatility.
This enhancement is a significant step forward in Tesla’s journey to develop robots that can safely and effectively navigate real-world environments while interacting with humans. The improved hands not only show engineering progress but also underlie Tesla’s vision for a future where humanoid robots play a more active and helpful role in daily life.
Read Announcement
Tesla FDA Events - Frequently Asked Questions
As of now, Tesla (TSLA) has not received any FDA approvals for its therapy in the last two years.
In the past two years, Tesla (TSLA) has reported FDA regulatory activity for CONVOY.
The most recent FDA-related event for Tesla occurred on November 29, 2024, involving CONVOY. The update was categorized as "Provided Update," with the company reporting: "Tesla Inc. has introduced a major enhancement to its humanoid robot, Optimus, featuring new hands."
Currently, Tesla has one therapy (CONVOY) targeting the following condition: To test the Brain-to-Computer-interface (BCI) N1 Implant with assistive robotic arms..
More FDA Event Resources from MarketBeat
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
This page (NASDAQ:TSLA) was last updated on 7/9/2025 by MarketBeat.com Staff
